AKARI THERAPEUTICS PLC-ADR (AKTX) Fundamental Analysis & Valuation

NASDAQ:AKTX • US00972G2075

Current stock price

3.54 USD
-0.93 (-20.81%)
Last:

This AKTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. AKTX Profitability Analysis

1.1 Basic Checks

  • AKTX had negative earnings in the past year.
  • AKTX had a negative operating cash flow in the past year.
  • In the past 5 years AKTX always reported negative net income.
  • In the past 5 years AKTX always reported negative operating cash flow.
AKTX Yearly Net Income VS EBIT VS OCF VS FCFAKTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M

1.2 Ratios

  • AKTX has a Return On Assets of -36.12%. This is comparable to the rest of the industry: AKTX outperforms 58.99% of its industry peers.
  • AKTX's Return On Equity of -61.06% is in line compared to the rest of the industry. AKTX outperforms 56.48% of its industry peers.
Industry RankSector Rank
ROA -36.12%
ROE -61.06%
ROIC N/A
ROA(3y)-101.69%
ROA(5y)-116.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AKTX Yearly ROA, ROE, ROICAKTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50K -100K -150K

1.3 Margins

  • AKTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AKTX Yearly Profit, Operating, Gross MarginsAKTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. AKTX Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, AKTX has an improved debt to assets ratio.
AKTX Yearly Shares OutstandingAKTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M 5M
AKTX Yearly Total Debt VS Total AssetsAKTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

2.2 Solvency

  • AKTX has an Altman-Z score of -2.11. This is a bad value and indicates that AKTX is not financially healthy and even has some risk of bankruptcy.
  • AKTX's Altman-Z score of -2.11 is in line compared to the rest of the industry. AKTX outperforms 48.55% of its industry peers.
  • AKTX has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
  • AKTX has a Debt to Equity ratio of 0.03. This is comparable to the rest of the industry: AKTX outperforms 44.29% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -2.11
ROIC/WACCN/A
WACCN/A
AKTX Yearly LT Debt VS Equity VS FCFAKTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M

2.3 Liquidity

  • AKTX has a Current Ratio of 0.44. This is a bad value and indicates that AKTX is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Current ratio of AKTX (0.44) is worse than 91.88% of its industry peers.
  • AKTX has a Quick Ratio of 0.44. This is a bad value and indicates that AKTX is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.44, AKTX is doing worse than 91.49% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.44
Quick Ratio 0.44
AKTX Yearly Current Assets VS Current LiabilitesAKTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. AKTX Growth Analysis

3.1 Past

  • The earnings per share for AKTX have decreased strongly by -430.00% in the last year.
EPS 1Y (TTM)-430%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • AKTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.64% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y98.9%
EPS Next 2Y41.39%
EPS Next 3Y18.67%
EPS Next 5Y12.64%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AKTX Yearly Revenue VS EstimatesAKTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2030 2031 2032 2033 50M 100M 150M
AKTX Yearly EPS VS EstimatesAKTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30 -40 -50

More info and screens

Find the best growth stocksShow best growing peers

0

4. AKTX Valuation Analysis

4.1 Price/Earnings Ratio

  • AKTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year AKTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AKTX Price Earnings VS Forward Price EarningsAKTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100 -150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AKTX Per share dataAKTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

  • A more expensive valuation may be justified as AKTX's earnings are expected to grow with 18.66% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.39%
EPS Next 3Y18.67%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AKTX Dividend Analysis

5.1 Amount

  • AKTX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AKTX Fundamentals: All Metrics, Ratios and Statistics

AKARI THERAPEUTICS PLC-ADR

NASDAQ:AKTX (4/6/2026, 4:30:01 PM)

3.54

-0.93 (-20.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-30
Earnings (Next)05-12
Inst Owners9.63%
Inst Owner Change0%
Ins Owners24.57%
Ins Owner Change0%
Market Cap126.52M
Revenue(TTM)N/A
Net Income(TTM)-17.30M
Analysts84
Price TargetN/A
Short Float %62.57%
Short Ratio0.48
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)100%
Min EPS beat(2)100%
Max EPS beat(2)100%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-8.62%
PT rev (3m)-41.54%
EPS NQ rev (1m)-3900%
EPS NQ rev (3m)-2400%
EPS NY rev (1m)0%
EPS NY rev (3m)37.04%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.47
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-18.6
EYN/A
EPS(NY)-0.02
Fwd EYN/A
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS0
BVpS0.79
TBVpS-0.39
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -36.12%
ROE -61.06%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-101.69%
ROA(5y)-116.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.44
Quick Ratio 0.44
Altman-Z -2.11
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-430%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y98.9%
EPS Next 2Y41.39%
EPS Next 3Y18.67%
EPS Next 5Y12.64%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y31.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y15.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.81%
OCF growth 3YN/A
OCF growth 5YN/A

AKARI THERAPEUTICS PLC-ADR / AKTX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of AKARI THERAPEUTICS PLC-ADR (AKTX) stock?

ChartMill assigns a fundamental rating of 1 / 10 to AKTX.


What is the valuation status of AKARI THERAPEUTICS PLC-ADR (AKTX) stock?

ChartMill assigns a valuation rating of 0 / 10 to AKARI THERAPEUTICS PLC-ADR (AKTX). This can be considered as Overvalued.


Can you provide the profitability details for AKARI THERAPEUTICS PLC-ADR?

AKARI THERAPEUTICS PLC-ADR (AKTX) has a profitability rating of 1 / 10.


How financially healthy is AKARI THERAPEUTICS PLC-ADR?

The financial health rating of AKARI THERAPEUTICS PLC-ADR (AKTX) is 1 / 10.


What is the earnings growth outlook for AKARI THERAPEUTICS PLC-ADR?

The Earnings per Share (EPS) of AKARI THERAPEUTICS PLC-ADR (AKTX) is expected to grow by 98.9% in the next year.